Altimmune closed a $75M direct offering to fund Phase 3 pemvidutide trials for MASH, leveraging recent positive Phase 2b data and FDA Breakthrough Therapy status. Pemvidutide’s dual GLP-1/glucagon ...
Retatrutide met primary and key secondary endpoints in a 2339-participant, randomized, double-blind, placebo-controlled phase 3 trial, demonstrating clinically meaningful weight reduction across 4, 9, ...
Immunotherapy for Advanced Non–Small Cell Lung Cancer: A Decade of Progress In contemporary phase I trials, which often include drugs developed with a deep understanding of biology and with the use of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results